Prevalence studies indicate that around 5 to 15% of the exposed health care workforce is sensitized to natural rubber latex (NRL). The general population exhibits a much lower prevalence of NRL sensitization (around 6 to 7%) (1, 3, 4, 11, 12, 16, 17, 18). These prevalence estimates are based on seroprevalence with a variety of assays. The marked discrepancies in seroprevalence rates and risk estimates among studies were thought to be due to the reduced sensitivity of these assays compared to puncture skin tests (PST) (7) or overestimation of prevalence with a variety of assays. The marked discrepancies in the diagnostic performances of these serological assays have not been performed using well-characterized skin-testing reagents.

Receiver Operating Characteristics Analyses of Food and Drug Administration-Cleared Serological Assays for Natural Rubber Latex-Specific Immunoglobulin E Antibody

RAYMOND E. BIAGINI,1* EDWARD F. KRIEG,1 LYNNE E. PINKERTON,2 and ROBERT G. HAMILTON3

Division of Applied Research and Technology1 and Division of Surveillance Hazard Evaluations and Field Studies;2 National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Public Health Service, Department of Health and Human Services, Cincinnati, Ohio 45226, and Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224*

Received 21 May 2001/Returned for modification 7 August 2001/Accepted 22 August 2001

Receiver operating characteristics (ROC) analyses to evaluate and compare the diagnostic accuracy of Food and Drug Administration (510K)-cleared natural rubber latex (NRL)-specific immunoglobulin E (IgE) antibody immunoassays have not been performed using well-characterized skin-testing reagents. Sera were collected from 311 subjects (131 latex puncture skin test [PST] positive and 180 PST negative). All masked, coded sera were analyzed for latex-specific IgE antibodies in the Diagnostic Products Corporation microplate AlaSTAT, HYCOR HY-TEC RAST, and Pharmacia-Upjohn CAP System RAST FEIA (CAP). Diagnostic accuracy was evaluated using GraphRoc for Windows software to construct and analyze ROC curves in relation to the subjects’ PST status and the results of the immunoassays. The ROC areas under the curve (AUCs) ± standard error based on PST for the three diagnostic tests were 0.858 ± 0.024, 0.869 ± 0.024, and 0.924 ± 0.017, respectively, for AlaSTAT, CAP, and HY-TEC. The HY-TEC system had a significantly greater AUC based on PST than those observed for AlaSTAT (P < 0.05) and CAP (P < 0.05). When the diagnostic tests were probed as to the cutoffs giving maximal diagnostic efficiency compared to PST, CAP and AlaSTAT yielded values of <0.35 kU/liter of allergen IgE (kU/liter) and <0.35 kU/liter while the HY-TEC assay yielded 0.11 kU/liter. The diagnostic efficiencies based on PST in our cohort at these cutoffs were 87.1, 88.1, and 88.7%, respectively. The HY-TEC assay had a significantly greater AUC than CAP and AlaSTAT using PST as a diagnostic discriminator in our cohort. When the HY-TEC system was probed at its maximally efficient cutoff (0.11 kU/liter) versus HYCOR’s recommended cutoff of 0.05 kU/liter, a loss of sensitivity of 8.4% was observed with a gain in specificity of 19.5%.

Current FDA-cleared latex IgE assays produced a substantial number (25 to 28%) of false-negative and false-positive IgE antibody results. In order to investigate whether a partial explanation of the poor association between serological assays and PST for the diagnosis of latex hypersensitivity was due to systematic biases within the assays themselves, we undertook a comprehensive analysis of their performance. Clinical accuracy and positive threshold cutoffs for latex-specific IgE using the three presently FDA-cleared diagnostic tests, CAP System RAST FEIA (CAP) (Pharmacia-UpJohn Corporation, Upplands, Sweden), the AlaSTAT Microplate Assay (Diagnostic Products Corporation, Los Angeles, Calif.), and the HY-TEC EIA System (HYCOR Biomedical, Irvine, Calif.), were compared.

* Corresponding author. Mailing address: Division of Applied Research and Technology, National Institute for Occupational Safety and Health, MS-C26, 4676 Columbia Parkway, Cincinnati, OH 45226. Phone: (513) 533-8196. Fax: (513) 533-8494. E-mail: reb4@cdc.gov.
it is a measure of specificity (13). The area under the ROC curve (AUC) is an overall index of diagnostic accuracy that is not dependent on a decision threshold. An AUC of 0.5 indicates that the discriminatory ability of the test is no better than chance. An AUC of 1.0 indicates perfect discriminatory ability.

**MATERIALS AND METHODS**

**Human sera.** The Human Subjects Review Board of the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, approved the study design. Subjects (n = 311) were recruited from across the United States as part of an FDA-reviewed multicenter latex skin-testing study protocol (8). Following informed consent, the subject’s latex hypersensitivity history status was determined based on an extensively critiqued clinical history questionnaire (6). Whole blood was collected by venipuncture, clotted for 30 min, and centrifuged, and the serum was aliquoted, coded, and frozen until the time of analysis. All subjects underwent PST with a bifurcated needle with saline, histamine (1.8 mg/ml; Allermed Laboratories, San Diego, Calif.), and nonammoniated latex (Greer Laboratories, Lenoir, N.C.) at 1, 100, and 1,000 mg/ml as described elsewhere (12, 15). Sera were collected from 311 (131 latex PST-positive and 180 PST-negative) subjects. Separate quality control sera containing 1 to 3 IU of latex-specific IgE/ml were analyzed in multiple runs of each assay to assess between-assay variation. Inclusion and exclusion criteria, as well as a more detailed description of the FDA-approved study which was the basis of the samples obtained for the present study, are given elsewhere (6, 8).

**Serological analyses.** NRL-specific IgE antibody was measured in the three FDA-cleared immunoassays briefly described below using coded sera in a masked mode. After submission of the data, an independent investigator at NIOSH broke the latex hypersensitivity history and PST codes.

CAP was performed by the Johns Hopkins University Division of Allergy and Clinical Immunology Reference Laboratory (Baltimore, Md.) in accordance with the manufacturer’s instructions using reagents purchased from Pharmacia-Upjohn Corporation. The assay is a solid-phase immunofluorometric assay in which IgE antibody is bound to latex allergosorbent (K82; sponge matrix) and detected with β-galactosidase-labeled rabbit polyclonal anti-human IgE and 4-methylumbelliferyl-β-D-galactoside substrate. The manufacturer recommends considering results of ≥0.35 kU/liter positive. The Biological Monitoring Laboratory Section at NIOSH (Cincinnati, Ohio) performed the AlaSTAT Microplate Assay in accordance with the manufacturer’s instructions using reagents purchased from Diagnostic Products Corporation. The assay is a liquid phase immunoenzymatic assay in which latex allergen (K82) that is coupled to soluble biotin-(polymer or copolymer matrix binds antibody. The complex is then bound to biotin-coated microtiter plate wells with the addition of avidin, and bound IgE is detected with peroxidase-labeled monoclonal anti-human IgE and 3,3′,5,5′-tetramethylbenzidine substrate in buffered H2O2. The manufacturer recommends considering results of ≥0.05 kU/liter positive.

The company (HYCOR Biomedical) laboratory performed the HY-TEC EIA System according to the instructions in the package insert. The assay is an enzyme immunoassay in which IgE antibody binds to latex (K82) cellulose disks and is detected with peroxidase-conjugated mouse anti-human IgE and p-nitrophenyl phosphate substrate in dichotranolamine buffer. The manufacturer recommends considering results of ≥0.05 kU/liter positive (modified scoring system).

**Statistical analyses:** Curves were prepared and analyzed using GraphRoc for Windows (version 2.0; downloaded from http://members.tripod.com/erostat/GRdownload.htm). Data on 311 samples for which we had data from all three analyses were analyzed. A two-tailed type I error level of 0.05 was considered significant. Statistical analyses were performed using SPSS (version 9; SPSS, Inc., Chicago, Ill.) and SAS (SAS Institute Inc., Cary, N.C.). Assay performance was computed using the following definitions (where FN is a false-negative diagnostic test result, FP is a false-positive diagnostic test result, TP is a true-positive diagnostic test result, and TN is a true-negative diagnostic test result). Sensitivity (TP/(TP + FN) · 100) was defined as the percentage of positive tests in subjects with a positive latex PST. Specificity (TN/(TN + FP) · 100) was defined as the percentage of negative tests in subjects with a negative PST. Predictive value for a positive test (TP/(TP + FP) · 100) describes the percentage of subjects with a positive test that have a positive PST. Predictive value for a negative test (TN/(TN + FN) · 100) is the percentage of subjects with a negative test that have a negative PST. Efficiency (TP/(TN + FP + TN + FN) · 100) describes the percentage of subjects correctly classified as having a positive and negative latex PST. McNemar’s test was used to assess statistical differences among the sensitivities, specificities, efficiencies, and positive and negative predictive values of the different methods. An averaging method (10) was employed to minimize bias in cases where sera had results below the limit of detection of the assay. For testing of the significance of differences between AUCs for multiple ROC curves, the method of Hanley and McNeil (9) was used. Confidence intervals (95%) were calculated from a normal distribution as previously described by Galen and Peters (5). The thresholds that maximized diagnostic efficiency for our cohort were chosen as the optimal cutoffs. If the optimal decision threshold obtained in the ROC analysis was different from the manufacturer’s recommended threshold, a Bayesian analysis was conducted to obtain predictive values for a positive test, predictive values for a negative test, and efficiency of the test for both decision thresholds using the following formulas: PPV = Se(P)/[Se(P) + (1 – Sp(1 – P))]; NPV = Sp(1 – P)/(1 – Se(1 – Sp) + Sp(1 – P)), where PPV is the predictive value of a positive test, NPV is the predictive value of a negative test, Se is sensitivity, Sp is specificity, and P is prevalence.

**RESULTS**

The reproducibilities of the three assays have already been reported (7). Briefly, intra-assay agreement was evidenced by 96% concordance of positivity among results of the 22 coded duplicate (split) specimens in all three assays using the respective manufacturers’ recommended cutoffs. Intra-assay coefficients of variation for the interpolated kU/liter results obtained with the 17 split sera from PST-positive subjects were 24.9 (CAP), 16.1 (AlaSTAT), and 15.2% (HY-TEC). Between-assay variation for the three assays was 10.5% (n = 36; mean level, 0.78 IU/ml), 12.4% (n = 12; mean level, 1.61 kU/liter), and 20.3% (n = 69; mean level, 2.41 kU/ml) for the CAP, ALASTAT, and HY-TEC assays, respectively. The ROC AUCs ± standard error based on PST (Fig. 1) for the three diagnostic tests were 0.858 ± 0.024, 0.869 ± 0.023, and 0.924 ± 0.017, respectively, for AlaSTAT, CAP, and HY-TEC. The HY-TEC system had a significantly greater AUC based on PST than those observed for both AlaSTAT (P < 0.05) and CAP (P < 0.05) assays. When the diagnostic tests were probed as to the cutoffs giving maximal diagnostic efficiency for PST, the CAP and AlaSTAT assays yielded values of <0.35 kU/liter and <0.35 kU/liter, while the HY-TEC assay yielded 0.11 kU/liter. The diagnostic efficiencies based on PST at these cutoffs were 87.1, 88.1, and 88.7% for AlaSTAT, CAP, and HY-TEC, respectively. The diagnostic sensitivity (P < 0.001) and nega-


ROC ANALYSES FOR LATEX HYPERSENSIBILITY

TABLE 1. Diagnostic accuracies of IgE anti-latex assays at cutoffs yielding maximum diagnostic efficiency

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Diagnostic accuracy*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ALA (&lt;0.35 kU/liter)</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>73.3 (65.7–80.9)</td>
</tr>
<tr>
<td>Specificity</td>
<td>97.2 (94.8–99.6)</td>
</tr>
<tr>
<td>Positive predictive value</td>
<td>95.1 (90.8–99.3)</td>
</tr>
<tr>
<td>Negative predictive value</td>
<td>83.3 (78.3–88.4)</td>
</tr>
<tr>
<td>Efficiency</td>
<td>87.1 (83.4–90.9)</td>
</tr>
</tbody>
</table>

* Percent; the numbers in parentheses are the 95% confidence interval (n = 311).
* Cutoff value yielding maximal diagnostic efficiency.
* Performance parameters of HY-TEC assay based on PST are significantly different from those displayed by the CAP and AlaSTAT systems. *, P < 0.05; **, P < 0.001.


tive predictive value (P < 0.05) of the HY-TEC assay, based on PST, were significantly greater than those displayed by the CAP and AlaSTAT systems, while the specificity (P < 0.05) was significantly lower. These results are shown in Table 1. Table 2 indicates the positive and negative predictive values and efficiency of the HY-TEC assay using the manufacturer’s recommended decision threshold and the optimal decision threshold obtained in the ROC analysis for various prevalence situations.

**DISCUSSION**

Clinical accuracy is the basic ability to discriminate between two subclasses of subjects where there is some clinically relevant reason to do so. This concept of clinical accuracy refers to the quality of the initial classification of the subjects based on a diagnostic discriminator. The accuracy of the probing provided by the discriminator is the basis of any comparisons of the usefulness of diagnostic testing. ROC curves yield a simple graphical method to evaluate the trade-offs obtained between sensitivity and specificity across all test cutoffs. In the present work, we use a discriminator (PST) which has been rigorously validated (6, 8), yielding the possibility to determine, with some confidence, the accuracy of the diagnostic tests used to dichotomize subjects.

Choosing the optimal decision is a trade-off between optimizing sensitivity and specificity. The optimal decision thresholds obtained in this analysis were selected assuming that the cost of a false-positive result and the cost of a false-negative result were equal, but this may not be the case in some clinical applications. The optimal decision threshold for a specific clinical application involves a number of factors that are not properties of the testing system; rather they are properties of the clinical application. These include prevalence, the outcomes and the relative values of those outcomes, the costs to the patient and others of incorrect classification (false-positive and false-negative classifications), and the costs and benefits of various interventions. These characteristics interact with test results to affect usefulness. Methods have been developed for determining the optimal decision threshold based on the prevalence and the costs of incorrect classification (14, 21). In general, a higher decision threshold is preferred if the prevalence is low or if the cost of a false-positive result is greater than the cost of a false-negative result. A lower decision threshold is preferred if the prevalence is high or if the cost of a false-negative result is greater than the cost of a false-positive result. We presented data for the HY-TEC assay demonstrating the effects of using the manufacturer’s recommended decision threshold and the optimal decision threshold we obtained from the ROC analysis. These data assume that sensitivity and specificity are inherent properties of the test and thus independent of prevalence. Although this is generally assumed to be the case, sensitivity and specificity may vary among different subpopulations and thus are dependent on the composition of the population under study (2). Unlike sensitivity and specificity, diagnostic efficiency is dependent on disease prevalence, and the prevalence in the study sample may not be representative of the prevalence in the target population in some clinical applications; thus, the diagnostic efficacies reported for the assays cannot be generalized to other clinical applications. Another disadvantage of comparing diagnostic efficiencies of different tests is that two tests may have the same diagnostic efficiency but perform quite differently. For example, one test may result in many false positives and few false negatives whereas another test may result in many false negatives but few false positives.

ROC analyses also provide support for the proposed hypothesis (15) that IgE antibody assays can detect different subsets of IgE antibody of a given specificity, possibly as a result of differential specificities of their allergen-containing reagents. There are several possible reasons for this: different batches of source latex are known to vary up to 25-fold in total allergen content (19); sensitized individuals produce specific IgE antibodies to at least 8, and possibly as many as 11, Hevea allergens, Hev b1 to Hev b11 (http://dmd.nih.go.jp/latex/allergen-e.html); and all of these allergens differ in structure, size, net charge (pI), relative allergenicity, and abundance in NRL, and many have been sequenced (http://www.iit.edu/~sgendel/nonfdaall.htm). Moreover, aqueous latex extracts vary widely in their relative contents of rubber particle-associated proteins (Hev b1, or rubber elongation factor, 14.6- or 58-kDa tetramer, and Hev b3, or prenyltransferase or small rubber particle protein, 23 to 27 kDa). The relative contents and ratios of Hevs in the final allergen preparation most probably could affect the diagnostic accuracy of a specific test. Other potential causes of

**TABLE 2. Positive predictive value, negative predictive value, and efficiency of the HY-TEC assay**

<table>
<thead>
<tr>
<th>Decision threshold (kU/liter)</th>
<th>Prevalence (%)</th>
<th>Positive predictive value (%)</th>
<th>Negative predictive value (%)</th>
<th>Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05</td>
<td>5</td>
<td>15.3</td>
<td>99.4</td>
<td>74.2</td>
</tr>
<tr>
<td>25</td>
<td>55.3</td>
<td>96.3</td>
<td>77.9</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>77.4</td>
<td>89.7</td>
<td>82.5</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>91.1</td>
<td>74.4</td>
<td>87.0</td>
<td></td>
</tr>
<tr>
<td>0.11</td>
<td>75</td>
<td>37.8</td>
<td>99.1</td>
<td>92.3</td>
</tr>
<tr>
<td>25</td>
<td>79.4</td>
<td>93.4</td>
<td>79.4</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>92.0</td>
<td>84.7</td>
<td>88.0</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>97.2</td>
<td>64.8</td>
<td>85.6</td>
<td></td>
</tr>
</tbody>
</table>

* Using the manufacturer’s recommended positive decision threshold (≥0.05 kU/liter) and the optimal decision threshold obtained in the ROC analysis (0.11 kU/liter).
allergen-containing-reagent heterogeneity include variable stability during storage and variable binding of allergen to labels (e.g., biotinylated copolymer in AlaSTAT) or solid supports (spont in CAP; cellulose disk in HY-TEC) (15).

In the present study, we have examined the diagnostic accuracies of three FDA-cleared latex-specific IgE antibody immunoassays using 311 sera that were collected from subjects participating in a multicenter latex skin-testing study (6, 8). The diagnostic performances of the three assays using the manufacturers’ recommended decision thresholds have already been described (7). We extend those findings by comparing the diagnostic accuracies of the three FDA-cleared anti-latex IgE tests by the use of ROC curve analyses. The results of these analyses indicate that the HY-TEC system yields a significantly greater AUC than CAP or AlaSTAT when PST is used as a diagnostic discriminator. At this cutoff, the HY-TEC system has an increased sensitivity of as much as 9.9% over CAP and AlaSTAT (at their respective maximally efficient cutoffs of <0.35 kU/liter and <0.35 kU/liter) with a reduction in specificity of only 4.4%, clearly indicating that it is the most sensitive of the three tests at their optimal thresholds in a simultaneous comparison. It should be kept in mind that the HY-TEC assay using the 0.11-kU/liter cutoff misclassified 16.8% of PST-positive individuals as negative and 7.2% of PST-negative individuals positive. For comparison, the HY-TEC test using a 0.05-kU/liter cutoff yields a diagnostic sensitivity of 91.6% with a diagnostic specificity of 73.3%, while at 0.11 kU/liter, the diagnostic specificity is 83.2% with a diagnostic specificity of 92.8%. Comparing the two HY-TEC cutoffs (0.05 and 0.11 kU/liter) indicates a loss of sensitivity at the higher cutoff of 8.4% with a gain in specificity of 19.5%. The positive and negative predictive values and efficiency of the HY-TEC assay using the manufacturer’s recommended decision threshold and the optimal decision threshold obtained in the ROC analysis will change (Table 2) depending on prior probability (prevalence).

ROC analysis is uniquely suited to situations where multiple unknown complex multivariate responses are being examined simultaneously. In this case, PST with NRL (which is a complex mixture of numerous [≈240] proteins) was evaluated using FDA-cleared serum tests which potentially contain multiple similar or modified latex antigens. Although precise chemical correlations between the skin test and serum antibody specificities are difficult to know with certainty, the presence of a validated discriminator (PST) allows the mathematical interpretation of diagnostic-test responses at increasing positive-negative thresholds and their comparison to the presence or absence of disease. Finally, care should be exercised when interpreting negative IgE antibody results from the CAP and AlaSTAT assays, even at their manufacturers’ recommended positive cutoffs, since these assays misclassify approximately 25% of subjects who are skin test positive as IgE antibody negative (false negative). Care should also be exercised when interpreting positive IgE antibody results from the HY-TECH assay, even at the manufacturer’s recommended positive cutoffs, since this assay misclassifies approximately 25% of PST-negative subjects as IgE antibody positive (false positives).

ACKNOWLEDGMENTS

The NIOSH aspects of this work were supported by an interagency agreement between NIOSH and NIEHS (Y02ES10189). The Johns Hopkins University segment of this work has been supported by NIH grant AI-31867 and Allegiance Healthcare Corporation. Hamilton and Johns Hopkins University are entitled to royalties derived from the sale of latex skin-testing reagents prepared by Greer Laboratories, Inc., used in the skin-testing portion of this study. The terms of this arrangement have been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policy.

We thank Doug Sharpnack, Director, Division of Applied Research and Technology, NIOSH, for procuring the data for this study. In addition, we appreciate the excellent technical assistance of S. Robertson, D. Murphy, B. MacKenzie, and J. Wisenauer. We also wish to thank the Multi-Center Latex Skin Testing Study Task Force of the American Academy of Allergy, Asthma, and Immunology: Robert E. Esch, Greer Laboratories; James A. MacLean, Massachusetts General Hospital, Boston, Mass.; Gary J. Stadtmueller, Mr. Sinai Medical Center, New York, N.Y.; David Husman, Greer Laboratories; Mark Babuk, Central Plains Clinic, Sioux Falls, S.D.; David B. K. Golden, Baltimore, Md.; David F. Graith, Park Nicollet Clinic, Minneapolis, Minn.; Judy S. Kelloway, Park Nicollet Clinic; Kevin J. Kelly, Medical College of Wisconsin, Milwaukee; Kenneth T. Kim, Allergy Asthma and Respiratory Care Center, Long Beach, Calif.; Christopher C. Randol, Waterbury, Conn.; Jay E. Slater, Children’s National Medical Center, Washington, D.C.; David I. Bernstein, University of Cincinnati, Cincinnati, Ohio; and Michael B. Wein, Vero Beach, Fla.

REFERENCES